{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T07:20:29Z","timestamp":1792653629363,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T00:00:00Z","timestamp":1661558400000},"content-version":"am","delay-in-days":299,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20K07892"],"award-info":[{"award-number":["20K07892"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["20FC1030"],"award-info":[{"award-number":["20FC1030"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.msard.2021.103222","type":"journal-article","created":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T02:22:20Z","timestamp":1629771740000},"page":"103222","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Five-year visual outcomes after optic neuritis in anti-MOG antibody-associated disease"],"prefix":"10.1016","volume":"56","author":[{"given":"Tetsuya","family":"Akaishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Himori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Takeshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuro","family":"Misu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Takai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juichi","family":"Fujimori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Fujihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Nakazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.msard.2021.103222_bib0001","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1177\/1352458515581438","article-title":"Treatment of acute relapses in neuromyelitis optica: steroids alone versus steroids plus plasma exchange","volume":"22","author":"Abboud","year":"2016","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.103222_bib0002","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jneuroim.2016.09.007","article-title":"Different etiologies and prognoses of optic neuritis in demyelinating diseases","volume":"299","author":"Akaishi","year":"2016","journal-title":"J. Neuroimmunol."},{"issue":"1","key":"10.1016\/j.msard.2021.103222_bib0003","doi-asserted-by":"crossref","first-page":"13890","DOI":"10.1038\/s41598-020-70919-w","article-title":"Progressive patterns of neurological disability in multiple sclerosis and neuromyelitis optica spectrum disorders","volume":"10","author":"Akaishi","year":"2020","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.msard.2021.103222_bib0004","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1212\/WNL.0000000000012175","article-title":"Difference in the source of anti-AQP4-IgG and anti-MOG-IgG antibodies in CSF in patients with neuromyelitis optica spectrum disorder","volume":"97","author":"Akaishi","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2021.103222_bib0005","doi-asserted-by":"crossref","first-page":"932","DOI":"10.3389\/fneur.2020.00932","article-title":"Rapid administration of high-dose intravenous methylprednisolone improves visual outcomes after optic neuritis in patients with AQP4-IgG-positive NMOSD","volume":"11","author":"Akaishi","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2021.103222_bib0006","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.msard.2017.02.015","article-title":"Clinical outcomes and predictive factors related to good outcomes in plasma exchange in severe attack of NMOSD and long extensive transverse myelitis: case series and review of the literature","volume":"13","author":"Aungsumart","year":"2017","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"11","key":"10.1016\/j.msard.2021.103222_bib0007","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/S0161-6420(94)31103-1","article-title":"The course of visual recovery after optic neuritis. Experience of the optic neuritis treatment trial","volume":"101","author":"Beck","year":"1994","journal-title":"Ophthalmology"},{"key":"10.1016\/j.msard.2021.103222_bib0008","article-title":"Plasma exchange in severe attacks of neuromyelitis optica","volume":"2012","author":"Bonnan","year":"2012","journal-title":"Mult. Scler. Int."},{"key":"10.1016\/j.msard.2021.103222_bib0009","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3389\/fneur.2018.00888","article-title":"Diagnosis and treatment of NMO spectrum disorder and MOG-encephalomyelitis","volume":"9","author":"Borisow","year":"2018","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2021.103222_bib0010","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ajo.2018.07.020","article-title":"Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: clinical characteristics, radiologic clues, and outcome","volume":"195","author":"Chen","year":"2018","journal-title":"Am. J. Ophthalmol."},{"issue":"11","key":"10.1016\/j.msard.2021.103222_bib0011","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1111\/ene.13753","article-title":"Acute idiopathic optic neuritis: not always benign","volume":"25","author":"Deschamps","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2021.103222_bib0012","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.3389\/fimmu.2018.02753","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disorders: toward a new spectrum of inflammatory demyelinating CNS disorders?","volume":"9","author":"Di Pauli","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2021.103222_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.540156","article-title":"AQP4-IgG and MOG-IgG related optic neuritis-prevalence, optical coherence tomography findings, and visual outcomes: a systematic review and meta-analysis","volume":"11","author":"Filippatou","year":"2020","journal-title":"Front. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2021.103222_bib0014","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1177\/1352458519895236","article-title":"MOG-antibody-associated disease is different from MS and NMOSD and should be classified as a distinct disease entity - commentary","volume":"26","author":"Fujihara","year":"2020","journal-title":"Mult. Scler."},{"issue":"4","key":"10.1016\/j.msard.2021.103222_bib0015","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1212\/NXI.0000000000000135","article-title":"Acute optic neuritis: unmet clinical needs and model for new therapies","volume":"2","author":"Galetta","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"1","key":"10.1016\/j.msard.2021.103222_bib0016","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11940-019-0541-x","article-title":"Treatment approaches for MOG-Ab-associated demyelination in children","volume":"21","author":"Hacohen","year":"2019","journal-title":"Curr. Treat Options Neurol."},{"issue":"7","key":"10.1016\/j.msard.2021.103222_bib0017","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1177\/1352458514555785","article-title":"Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease","volume":"21","author":"H\u00f6ftberger","year":"2015","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.103222_bib0018","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3389\/fneur.2020.00501","article-title":"Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide","volume":"11","author":"Hor","year":"2020","journal-title":"Front. Neurol."},{"issue":"10","key":"10.1016\/j.msard.2021.103222_bib0019","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.ophtha.2019.04.042","article-title":"Epidemiologic and clinical characteristics of optic neuritis in Japan","volume":"126","author":"Ishikawa","year":"2019","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.msard.2021.103222_bib0020","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/s12974-016-0719-z","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: brainstem involvement - frequency, presentation and outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J. Neuroinflammation."},{"issue":"2","key":"10.1016\/j.msard.2021.103222_bib0021","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/cei.12271","article-title":"Neuromyelitis optica: clinical features, immunopathogenesis and treatment","volume":"176","author":"Jarius","year":"2014","journal-title":"Clin. Exp. Immunol."},{"issue":"10","key":"10.1016\/j.msard.2021.103222_bib0022","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.ophtha.2018.03.041","article-title":"Aquaporin-4 and myelin oligodendrocyte glycoprotein autoantibody status predict outcome of recurrent optic neuritis","volume":"125","author":"Jitprapaikulsan","year":"2018","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.msard.2021.103222_bib0023","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ana.24554","article-title":"Neuromyelitis optica: evaluation of 871 attacks and 1153 treatment courses","volume":"79","author":"Kleiter","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2021.103222_bib0024","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jns.2018.11.029","article-title":"The prevalence and prognostic value of myelin oligodendrocyte glycoprotein antibody in adult optic neuritis","volume":"396","author":"Liu","year":"2019","journal-title":"J. Neurol. Sci."},{"issue":"10","key":"10.1016\/j.msard.2021.103222_bib0025","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.12732","article-title":"Comparison of clinical outcomes of transverse myelitis among adults with myelin oligodendrocyte glycoprotein antibody vs aquaporin-4 antibody disease","volume":"2","author":"Mariano","year":"2019","journal-title":"JAMA Netw. Open"},{"issue":"9","key":"10.1016\/j.msard.2021.103222_bib0026","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1177\/1352458508096878","article-title":"Differential diagnosis of suspected multiple sclerosis: a consensus approach","volume":"14","author":"Miller","year":"2008","journal-title":"Mult. Scler."},{"issue":"12","key":"10.1016\/j.msard.2021.103222_bib0027","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1007\/s00417-010-1344-7","article-title":"Early high-dose intravenous methylprednisolone is effective in preserving retinal nerve fiber layer thickness in patients with neuromyelitis optica","volume":"248","author":"Nakamura","year":"2010","journal-title":"Graefes. Arch. Clin. Exp. Ophthalmol."},{"issue":"2","key":"10.1016\/j.msard.2021.103222_bib0028","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1212\/NXI.0000000000000322","article-title":"MOG antibody-positive, benign, unilateral, cerebral cortical encephalitis with epilepsy","volume":"4","author":"Ogawa","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"3","key":"10.1016\/j.msard.2021.103222_bib0029","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/WCO.0000000000000446","article-title":"Myelin oligodendrocyte glycoprotein antibodies: How clinically useful are they?","volume":"30","author":"Reindl","year":"2017","journal-title":"Curr. Opin. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2021.103222_bib0030","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","article-title":"Myelin oligodendrocyte glycoprotein antibodies in neurological disease","volume":"15","author":"Reindl","year":"2019","journal-title":"Nat. Rev. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2021.103222_bib0031","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","article-title":"Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders","volume":"82","author":"Sato","year":"2014","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2021.103222_bib0032","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1055\/s-0028-1124020","article-title":"The optic nerve","volume":"29","author":"Selhorst","year":"2009","journal-title":"Semin. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2021.103222_bib0033","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1620\/tjem.210.307","article-title":"Establishment of a new sensitive assay for anti-human aquaporin-4 antibody in neuromyelitis optica","volume":"210","author":"Takahashi","year":"2006","journal-title":"Tohoku J. Exp. Med."},{"issue":"5","key":"10.1016\/j.msard.2021.103222_bib0034","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/brain\/awm062","article-title":"Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre","volume":"130","author":"Takahashi","year":"2007","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.msard.2021.103222_bib0035","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"issue":"37","key":"10.1016\/j.msard.2021.103222_bib0036","first-page":"616","article-title":"The diagnosis and treatment of optic neuritis","volume":"112","author":"Wilhelm","year":"2015","journal-title":"Dtsch Arztebl. Int."},{"issue":"2","key":"10.1016\/j.msard.2021.103222_bib0037","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821004892?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821004892?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:57:37Z","timestamp":1761901057000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034821004892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":37,"alternative-id":["S2211034821004892"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.103222","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Five-year visual outcomes after optic neuritis in anti-MOG antibody-associated disease","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.103222","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103222"}}